The Pancreas Cancer Olaparib Ongoing (POLO) trial, demonstrated that Olaparib maintenance therapy prolongs progression-free survival compared to placebo in patients with pancreatic ductal adenocarcinoma and germline BRCA1/2 mutations after platinum-based first-line chemotherapy [40]. This evidence concerns the gene BRCA1 and pancreatic ductal adenocarcinoma.